Draft Guidance on Venlafaxine Hydrochloride

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Venlafaxine Hydrochloride

Form/Route: Extended Release Tablet/Oral

Recommended studies: 1 study

<table>
<thead>
<tr>
<th>Type of study: Fed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Design: Single-dose, two-treatment, two-period crossover in-vivo</td>
</tr>
<tr>
<td>Strength: 150 mg</td>
</tr>
<tr>
<td>Subjects: Healthy males and nonpregnant females, general population</td>
</tr>
<tr>
<td>Additional Comments: Due to safety concerns, bioequivalence studies under fasting conditions are not recommended.</td>
</tr>
</tbody>
</table>

Analytes to measure: Venlafaxine, and its metabolite O-desmethylvenlafaxine, in plasma.

Bioequivalence based on (90% CI): Venlafaxine

Waiver request of in-vivo testing: 37.5 mg, 75 mg, and 225 mg based on (i) acceptable bioequivalence studies on the 150 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

For modified release products, dissolution profiles on 12 dosage units each of test and reference products generated using USP Apparatus I at 100 rpm and/or Apparatus II at 50 rpm in at least three dissolution media (pH 1.2, 4.5 and 6.8 buffer) should be submitted in the application. If appropriate, agitation speeds may be increased and, if necessary, a small amount of surfactant may be added. Please include early sampling times of 1, 2, and 4 hours and continue every 2 hours until at least 80% of the drug is released, to provide assurance against premature release of drug (dose dumping) from the formulation. Specifications will be determined upon review of the data submitted in the application.

Recommended Feb 2010; Revised Mar 2010
Due to concerns of dose dumping from this drug product when taken with alcohol, please conduct additional dissolution testing using various concentrations of ethanol in the dissolution medium, as follows:

Testing Conditions: 900 mL, 0.1 N HCl, USP apparatus 2 (paddle) @50 rpm, with or without alcohol;

Test 1: 12 units tested according to the proposed method (with 0.1N HCl), with data collected every 15 minutes for a total of 2 hours

Test 2: 12 units analyzed by substituting 5% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours

Test 3: 12 units analyzed by substituting 20% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours

Test 4: 12 units analyzed by substituting 40% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours

Both test and reference listed drug (RLD) products must be tested accordingly and data must be provided on individual unit, means, range and %CV on both strengths.